Patents by Inventor Herve Poulet

Herve Poulet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
    Patent number: 11033616
    Abstract: The present invention relates to exogenous feline paramyxovirus genes, which are expressed from recombinant viral vector systems.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: June 15, 2021
    Inventors: Hervé Poulet, Veljko Nikolin, Abraham Johannes De Smit, Teshome Mebatsion
  • RECOMBINANT VIRAL VECTOR SYSTEMS EXPRESSING EXOGENOUS FELINE PARAMYXOVIRUS GENES AND VACCINES MADE THEREFROM
    Publication number: 20200206339
    Abstract: The present invention relates to exogenous feline paramyxovirus genes, which are expressed from recombinant viral vector systems.
    Type: Application
    Filed: February 20, 2019
    Publication date: July 2, 2020
    Inventors: Hervé POULET, Veljko NIKOLIN, Abraham Johannes DE SMIT, Teshome MEBATSION
  • Inactivated canine influenza vaccines and methods of making and uses thereof
    Patent number: 10617752
    Abstract: The present invention relates to canine influenza virus strains, and vaccines and compositions. The present invention also relates to reagents and methods allowing their detection, methods of vaccination as well as methods of producing these reagents and vaccines.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: April 14, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Yu-Wei Chiang, David Cureton, Herve Poulet
  • Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof
    Patent number: 10537632
    Abstract: The present disclosure encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs are formed by the CPV VP2 protein. Further, the disclosure broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: January 21, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Frederic David, Zahia Hannas-Djebbara, Herve Poulet, Jules Maarten Minke
  • FCV recombinant vaccines and uses thereof
    Patent number: 10434165
    Abstract: The present invention encompasses FCV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FCV antigens. The invention also encompasses recombinant vectors encoding and expressing FCV antigens, epitopes or immunogens which can be used to protect animals against FCV infection.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: October 8, 2019
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Herve Poulet, Frédéric Reynard
  • Canine Parvovirus (CPV) Virus-like Particle (VLP) Vaccines and uses thereof
    Publication number: 20190000965
    Abstract: The present disclosure encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs are formed by the CPV VP2 protein. Further, the disclosure broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
    Type: Application
    Filed: August 22, 2018
    Publication date: January 3, 2019
    Applicant: MERIAL, INC.
    Inventors: Frederic David, Zahia Hannas-Djebbara, Herve Poulet, Jules Maarten Minke
  • Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof
    Patent number: 10080798
    Abstract: The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: September 25, 2018
    Assignee: MERIAL INC.
    Inventors: Frederic David, Zahia Hannas-Djebbara, Herve Poulet, Jules Maarten Minke
  • Inactivated Canine Influenza Vaccines and Methods of Making and Uses Thereof
    Publication number: 20180250382
    Abstract: The present invention relates to canine influenza virus strains, and vaccines and compositions. The present invention also relates to reagents and methods allowing their detection, methods of vaccination as well as methods of producing these reagents and vaccines.
    Type: Application
    Filed: June 23, 2016
    Publication date: September 6, 2018
    Applicant: MERIAL INC.
    Inventors: Yu-Wei Chiang, David Cureton, Herve Poulet
  • FCV RECOMBINANT VACCINES AND USES THEREOF
    Publication number: 20180243399
    Abstract: The present invention encompasses FCV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FCV antigens. The invention also encompasses recombinant vectors encoding and expressing FCV antigens, epitopes or immunogens which can be used to protect animals against FCV infection.
    Type: Application
    Filed: August 16, 2016
    Publication date: August 30, 2018
    Applicant: MERIAL INC.
    Inventors: Herve Poulet, Frédéric Reynard
  • Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
    Patent number: 9856295
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: January 2, 2018
    Assignee: MERIAL INC.
    Inventors: Herve Poulet, Thierry Heidmann
  • Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
    Patent number: 9682138
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 20, 2017
    Assignee: MERIAL, INC.
    Inventors: Herve Poulet, Thierry Heidmann
  • Canine Parvovirus (CPV) Virus-like Particle (VLP) Vaccines and uses thereof
    Publication number: 20170087244
    Abstract: The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
    Type: Application
    Filed: September 14, 2016
    Publication date: March 30, 2017
    Applicant: MERIAL, INC.
    Inventors: Frederic David, Zahia Hannas-Djebbara, Herve Poulet, Jules Maarten Minke
  • Newcastle disease virus vectored herpesvirus vaccines
    Patent number: 9446118
    Abstract: The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: September 20, 2016
    Assignee: Merial, Inc.
    Inventors: Michel Bublot, Frederic Reynard, Herve Poulet, Frederic Raymond David
  • Recombinant Feline Leukemia Virus Vaccine Containing Optimized Feline Leukemia Virus Envelope Gene
    Publication number: 20150283228
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Application
    Filed: February 6, 2015
    Publication date: October 8, 2015
    Applicants: MERIAL LIMITED, UNIVERSITE PARIS-SUD, INSTITUT GUSTAVE ROUSSY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Herve Poulet, Thierry Heidmann
  • Newcastle Disease Virus Vectored Herpesvirus Vaccines
    Publication number: 20150157704
    Abstract: The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 11, 2015
    Applicant: MERIAL LIMITED
    Inventors: Michel Bublot, Frederic Reynard, Herve Poulet, Frederic Raymond David
  • Newcastle disease virus vectored herpesvirus vaccines
    Patent number: 8986706
    Abstract: The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: March 24, 2015
    Assignee: Merial, Inc.
    Inventors: Michel Bublot, Frederic Reynard, Herve Poulet, Frederic Raymond David
  • Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
    Patent number: 8980280
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: March 17, 2015
    Assignees: Merial, Inc., Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Sud
    Inventors: Herve Poulet, Thierry Heidmann
  • Recombinant Feline Leukemia Virus Vaccine Containing Optimized Feline Leukemia Virus Envelope Gene
    Publication number: 20150030623
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 29, 2015
    Applicants: Merial Limited, Centre National De la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Sud
    Inventors: Herve Poulet, Thierry Heidmann
  • Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
    Patent number: 8895027
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: November 25, 2014
    Assignees: Merial Limited, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Sud
    Inventors: Hervé Poulet, Thierry Heidmann
  • RECOMBINANT FELINE LEUKEMIA VIRUS VACCINE CONTAINING OPTIMIZED FELINE LEUKEMIA VIRUS ENVELOPE GENE
    Publication number: 20130022632
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Application
    Filed: February 2, 2012
    Publication date: January 24, 2013
    Inventors: Hervé Poulet, Thierry Heidmann